TAKHZYRO — DYAX CORP., approved 2023-02-03 (BLA761090).
3,576 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.